US FDA/NORD Partnership Will Further Increase Patient Involvement In Drug Development
Agency's agreement with rare disease advocacy group will facilitate patient meetings with review divisions, as well as enhance communication of safety information.
You may also be interested in...
Patient listening sessions, which are easier to schedule, have overtaken traditional patient-focused drug development meetings in terms of volume, although US FDA’s data may be incomplete.
Agency seeks legislative authority to update outdated generic drug labels when the reference product has been withdrawn.
Patient experience will be incorporated into agency orphan grant reviews, and outside rare disease experts will help make decisions.